An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022) - PubMed

Affiliations

• PMID: 36594709
• DOI: 10.1080/13543776.2022.2163162

Review

An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022)

Jinyun Dong et al. Expert Opin Ther Pat. 2022 Dec.

Abstract

Protein arginine methyltransferases (PRMTs), enzymes catalyzing the methylation of target proteins, play an essential role in maintaining functional homeostasis in normal physiology. Aberrant expressions and enhanced enzymatic activities of PRMTs have been closely associated with pathological states such as cancer, inflammatory, immune, metabolic, and neurodegenerative diseases. Therefore, the development of inhibitors targeting PRMTs has attracted a great deal of attention in both pharmaceutical industries and academic community. This review focuses on the small-molecule inhibitors targeting PRMTs in cancer therapy in the patents published since 2019. The recent clinical development is also discussed here. In recent years, the discovery of small-molecule PRMT inhibitors, especially PRMT5 inhibitors has become a rapidly expanding research area for cancer therapy. Although a number of potent PRMT inhibitors with different chemical scaffolds have been developed and nine of them have entered into clinical trials, their scaffolds are relatively less diverse. Sub-type selectivity should be considered in drug discovery as nonselective inhibition of PRMTs may cause undesirable pharmacological effects. Hence, the development of new effective inhibitors with isoform-specific and tumor-biased distributions remains an important area for further studies.

Keywords: PRMT1; PRMT5; Protein arginine methyltransferases; cancer; inhibitors.

Similar articles

• A patent review of arginine methyltransferase inhibitors (2010-2018).

  Li X, Wang C, Jiang H, Luo C. Li X, et al. Expert Opin Ther Pat. 2019 Feb;29(2):97-114. doi: 10.1080/13543776.2019.1567711. Expert Opin Ther Pat. 2019. PMID: 30640571 Review.

• Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance.

  Zhu Y, Xia T, Chen DQ, Xiong X, Shi L, Zuo Y, Xiao H, Liu L. Zhu Y, et al. Drug Resist Updat. 2024 Jan;72:101016. doi: 10.1016/j.drup.2023.101016. Epub 2023 Nov 3. Drug Resist Updat. 2024. PMID: 37980859 Review.

• Small Molecule Inhibitors of Protein Arginine Methyltransferases.

  Hu H, Qian K, Ho MC, Zheng YG. Hu H, et al. Expert Opin Investig Drugs. 2016;25(3):335-58. doi: 10.1517/13543784.2016.1144747. Epub 2016 Feb 16. Expert Opin Investig Drugs. 2016. PMID: 26789238 Free PMC article. Review.

• PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.

  Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, Wang Y, Awasthi S, Kaundal B, Wu S, Peng W, Mendillo ML, Lu Y, Jeter CR, Peng G, Liu J, Westin SN, Sood AK, Lewis MT, Das J, Yi SS, Bedford MT, McGrail DJ, Sahni N. Li Y, et al. Cell Rep Med. 2023 Dec 19;4(12):101326. doi: 10.1016/j.xcrm.2023.101326. Cell Rep Med. 2023. PMID: 38118413 Free PMC article.

• Functional Study of Leishmania braziliensis Protein Arginine Methyltransferases (PRMTs) Reveals That PRMT1 and PRMT5 Are Required for Macrophage Infection.

  Lorenzon L, Quilles JC Jr, Campagnaro GD, Azevedo Orsine L, Almeida L, Veras F, Miserani Magalhães RD, Alcoforado Diniz J, Rodrigues Ferreira T, Kaysel Cruz A. Lorenzon L, et al. ACS Infect Dis. 2022 Mar 11;8(3):516-532. doi: 10.1021/acsinfecdis.1c00509. Epub 2022 Feb 28. ACS Infect Dis. 2022. PMID: 35226477

Cited by

• Degraders in epigenetic therapy: PROTACs and beyond.

  Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, Shen L, Wang N, Herdewijn P, Zheng YC, Wang SQ, Chen XB. Dai XJ, et al. Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024. Theranostics. 2024. PMID: 38389844 Free PMC article. Review.

• Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor.

  Hung YH, Wang HC, Pan MR, Chen LT. Hung YH, et al. J Pers Med. 2024 Feb 20;14(3):224. doi: 10.3390/jpm14030224. J Pers Med. 2024. PMID: 38540967 Free PMC article.

• Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.

  Stitzlein LM, Adams JT, Stitzlein EN, Dudley RW, Chandra J. Stitzlein LM, et al. J Exp Clin Cancer Res. 2024 Jan 5;43(1):12. doi: 10.1186/s13046-023-02923-7. J Exp Clin Cancer Res. 2024. PMID: 38183103 Free PMC article. Review.

• Protein Arginine Methyltransferase 5 (PRMT5) Mutations in Cancer Cells.

  Rasheed S, Bouley RA, Yoder RJ, Petreaca RC. Rasheed S, et al. Int J Mol Sci. 2023 Mar 23;24(7):6042. doi: 10.3390/ijms24076042. Int J Mol Sci. 2023. PMID: 37047013 Free PMC article.

• Asymmetric and symmetric protein arginine methylation in methionine-addicted human cancer cells.

  Holtz AG, Lowe TL, Aoki Y, Kubota Y, Hoffman RM, Clarke SG. Holtz AG, et al. PLoS One. 2023 Dec 22;18(12):e0296291. doi: 10.1371/journal.pone.0296291. eCollection 2023. PLoS One. 2023. PMID: 38134182 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon